The 14 drugs that increased lifespan:
Cardiovascular / metabolic
- Atorvastatin (statin)
PDE5 inhibitor
- Sildenafil (Viagra)
Anti-inflammatory
- Naproxen
Estrogen / hormone-related (multiple hits)
- Estradiol
- Estriol
- Estraderm
- Vagifem
- Marvelon (ethinylestradiol + desogestrel contraceptive)
Other pharmaceuticals
- Lymecycline (antibiotic)
- Otomize (ear drop: steroid + antibiotic combo)
Vaccines
- Avaxim (hepatitis A vaccine)
- Revaxis (diphtheria, tetanus, polio booster)
ChatGPT summary:
Study Overview
- Researchers analyzed ~500,000 participants from the UK Biobank with up to ~20 years of follow-up.
- Looked at 400+ medications and compared users vs matched controls.
- Adjusted for confounders: age, sex, disease status, BMI, smoking, socioeconomic status.
- Goal: identify drugs associated with lower all-cause mortality (proxy for lifespan extension).
Core Finding
- The majority of drugs were linked to higher mortality.
- This is expected due to confounding by indication (people taking meds are often already sicker).
- After filtering for strong statistical signals → only 14 drugs showed lifespan-associated benefits.
Top Longevity-Associated Drug Classes
-
Statins (e.g., atorvastatin)
→ Likely via cardiovascular risk reduction over decades -
PDE5 inhibitors (e.g., sildenafil/tadalafil)
→ Possible mechanisms:- Improved vascular function
- Lower blood pressure
- Potential neuroprotective effects
- Or indirect: higher sexual activity / overall health marker
-
Hormone Replacement Therapy (HRT) (estrogen/estradiol)
→ Strong signal in women
→ Supported by known sex differences in lifespan -
SGLT2 inhibitors (newer diabetes drugs)
→ Among the strongest signals observed
→ Effects likely go beyond glucose control (multi-organ benefits)
Metformin Reality Check
- Despite its reputation, Metformin did NOT show a lifespan benefit in this dataset.
- Earlier studies suggesting benefit (even vs non-diabetics) have not consistently replicated.
- Mechanism still unclear and possibly too “broad/dirty” compared to newer drugs.
Important Nuance
- Not all “beneficial” drugs are overcoming disease risk.
- Some (like HRT or PDE5 inhibitors) are not strictly disease-driven, which reduces confounding.
- Socioeconomic factors were controlled for, but never perfectly.
Mechanistic Themes Emerging
Across both human data + animal work:
- Insulin sensitivity / glucose handling (SGLT2, diabetes pathways)
- Growth signaling (PI3K, mTOR, IGF-1)
- Cardiovascular function
- Hormonal environment
- Systemic damage response
Animal + Translational Work
-
Follow-up studies are testing these drugs in:
- Worms (C. elegans)
- Flies
- Fish
- Mice
- Goal: find conserved lifespan effects across species → higher chance of human relevance.
Biomarkers Angle
- Shift from just lifespan → biological age + mortality prediction
- Proteomics emerging as key tool
- One standout marker: GDF15
- Strongly correlated with age and mortality
- Possibly reflects damage or senescence burden
- Role (causal vs protective) still unclear
Limitations
- Observational study → cannot prove causation
- Confounding still present (even after adjustments)
- Only includes prescription drugs (no supplements, diet, etc.)
- Newer drugs (like SGLT2 inhibitors) have shorter follow-up
Big Picture Takeaways
- True human longevity signals are rare when rigorously analyzed
-
Some drug classes consistently stand out:
- SGLT2 inhibitors
- PDE5 inhibitors
- Estrogen therapies
- Statins (context-dependent)
- Metformin is not as strong as often claimed
-
Future direction:
- Cross-species validation
- Mechanism-first targeting (PI3K > mTOR may be underappreciated)
- Better biomarkers tied directly to mortality
Bottom Line
We’re moving from hype to signal. Out of 400+ drugs, only a handful show real-world associations with longer life. The next step is figuring out which of these actually cause the effect and why.